Friday, November 22, 2024 11/22/2024

Mechanisms regulating alloimmunization and tolerance with pathogen reduction and transfusion of allogeneic platelets

Award Number: R01HL133024
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

PROJECT SUMMARY/ABSTRACT: The long-term goal of this project is to better understand and prevent alloimmunization associated with the transfusion of platelets. Alloimmunization to donor MHC antigens following platelet transfusion occurs frequently and can cause complications such as platelet refractoriness and transplant rejection. UV-based pathogen reduction technologies (PRT) were designed to reduce the risk of transfusion-transmission of infectious disease. It has now been shown in mice that PRT has the additional benefit of both preventing alloresponses to treated platelets as well as modulating the response to subsequent untreated alloantigen exposure. The objective of this proposal is to establish a reductionist murine model in order to identify the mechanisms regulating the alloresponse to PRT treated platelets. This includes identifying the antigens required for the response to PRT treated versus untreated allogeneic PRP, identifying the cells that are presenting these antigens, and how this affects the development of a tolerant versus activating alloresponse in the transfusion recipient. The central hypothesis is that indirect presentation of class I MHC alloantigens from apoptotic treated cells drives the immunomodulation observed following transfusion of PRT treated allogeneic PRP; and that this effect is mediated by changes in the localization and activation state of tolerizing DCs, which in turn shifts the T cell response from activating to tolerogenic. The specific aims are: (1) To determine the type and source of alloantigens controlling the response to allogeneic PRP transfusion and the ability of PRT to modulate these responses in vivo; (2) To determine what APC populations are involved in the immune response to untreated and PRT treated allogeneic PRP transfusion in vivo; and (3) To determine the impact of PRT treated and untreated allogeneic PRP transfusion on the activation and differentiation of T cells in vivo. To identify the relevant alloantigens, donor mouse strains will be utilized that are allogeneic only in the MHC region, or only in the class I or class II MHC region, different components of the PRP will be transfused and cell death pathways triggered by PRT will be probed to identify the source of antigen. The relevant APC populations will be determined by measuring the activation, differentiation, and localization of DC subsets in the spleen following transfusion of PRT treated and untreated PRP, and by looking at the role of direct versus indirect presentation. The balance between activating and tolerogenic alloresponses will be assessed by examining the cytokine milieu in vivo and the activation and differentiation of T cells ex vivo following transfusion. Completion of this project will uncover the mechanisms responsible for the immunomodulation observed following PRT treated platelet transfusion and guide efforts to manipulate the immune response to alloantigens for clinical benefit. Increased understanding and control of this response could help improve patient outcomes following allogeneic transfusion, and transplants of solid organ and hematopoietic stem cells.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = -$2,432 )
2021	2018	VITALANT	6210 E OAK ST	SCOTTSDALE	AZ	85257	MARICOPA	USA	Blood Diseases and Resources Research	000	3	11/16/2020	NON-COMPETING CONTINUATION	-$2,432
														Subtotal = -$2,432

Issue Date FY: 2018 ( Subtotal = $356,175 )
2018	2018	BLOOD SYSTEMS, INC.	6210 E OAK ST	SCOTTSDALE	AZ	85257	MARICOPA	USA	Blood Diseases and Resources Research	000	3	4/19/2018	NON-COMPETING CONTINUATION	$356,175
														Subtotal = $356,175

Issue Date FY: 2017 ( Subtotal = $356,175 )
2017	2017	BLOOD SYSTEMS, INC.	6210 E OAK ST	SCOTTSDALE	AZ	85257	MARICOPA	USA	Lung Diseases Research	000	2	4/28/2017	NON-COMPETING CONTINUATION	$356,175
														Subtotal = $356,175

Issue Date FY: 2016 ( Subtotal = $356,175 )
2016	2016	BLOOD SYSTEMS INC	6210 EAST OAK STREET	TEMPE	AZ	85257		USA	Cardiovascular Diseases Research	000	1	5/31/2016	NEW	$356,175
														Subtotal = $356,175

Grand Total All Awards = $1,066,093

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanisms regulating alloimmunization and tolerance with pathogen reduction and transfusion of allogeneic platelets

Award Number: R01HL133024

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer